<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04548037</url>
  </required_header>
  <id_info>
    <org_study_id>NIMAO/2019-01/CH-01</org_study_id>
    <nct_id>NCT04548037</nct_id>
  </id_info>
  <brief_title>Assessment of Emotional Memory During Transient Global Amnesia</brief_title>
  <acronym>EMOTICTUS</acronym>
  <official_title>Assessment of Emotional Memory During Transient Global Amnesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are few studies on the role played by emotions in transient global amnesia (TGA), in&#xD;
      particular with regard to their impact on the functioning of memory. The study investigators&#xD;
      wish to better understand the link between episodic memory, emotional state and psychogenic&#xD;
      factors during TGA. It would be interesting to see if the patients suffering from TGA&#xD;
      triggered by a psychological shock process emotional information differently from those whose&#xD;
      TGA was triggered by an &quot;organic&quot; shock (physical effort, trauma, etc.). Finally, amnesic&#xD;
      stroke is a good model for better understanding the function of the hippocampus, in&#xD;
      particular of the CA1 region, in episodic memory.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Storage and retrieval capacities of information with a strong emotional valence in patients compared to healthy controls</measure>
    <time_frame>Day 0</time_frame>
    <description>International Affective Picture System (IAPS): number of correctly memorized images of each type of emotional content (15 positive, 15 negative and 15 neutral).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ability to judge the degree of activation and emotional value associated with images</measure>
    <time_frame>Day 0</time_frame>
    <description>Self Assessment Manikin (SAM)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in storage and retrieval capacities of information with a strong emotional valence in patients from baseline</measure>
    <time_frame>Day 3</time_frame>
    <description>International Affective Picture System (IAPS): number of correctly memorized images of each type of emotional content (15 positive, 15 negative and 15 neutral).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in storage and retrieval capacities of information with a strong emotional valence in patients from baseline</measure>
    <time_frame>Month 3</time_frame>
    <description>International Affective Picture System (IAPS): number of correctly memorized images of each type of emotional content (15 positive, 15 negative and 15 neutral).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Classification of event triggering transient global amnesia</measure>
    <time_frame>Day 0</time_frame>
    <description>Psychological/physiological</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>Day 0</time_frame>
    <description>Hamilton Scale: where score = 7 is absence of depression; 8-15 is minor depression and 16 or more is severe depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>Day 0</time_frame>
    <description>Beck Depression Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood</measure>
    <time_frame>Day 0</time_frame>
    <description>Befindlichkeits Skala Mood Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-score of the Groupe de REflexion pour l'Evaluation des Fonctions Exécutives (GREFEX) version of Stroop Test between patients and healthy control</measure>
    <time_frame>Day 0</time_frame>
    <description>Stroop Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeatable Battery for the Assessment of Neuropsychological Status between patients and healthy control</measure>
    <time_frame>Day 0</time_frame>
    <description>Repeatable Battery for the Assessment of Neuropsychological Status: 10 subtests combined into 5 index scores and 1 total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of hypometablic zones by PET compared to age- and sex-matched controls</measure>
    <time_frame>Day 0</time_frame>
    <description>Visual analysis of hippocampus and other topographies (Z-score); Statistical Parametric Mapping 12</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Amnesia, Transient Global</condition>
  <arm_group>
    <arm_group_label>Patients with transient global amnesia</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PET-CT examination</intervention_name>
    <description>The subject is placed in supine position, the head immobilized in a headrest. The imaging sequence begins with a scout view (viewing angle 90 °, 120 kV, 20 mA), then an X-ray scan is performed for the attenuation correction (120 kV, 5 mAs per slice, pitch 0.531, collimation 40 mm , FOV 70) and diagnostic CT scan (120 kV, 100-250 mA: auto mA, pitch 0.531, 40 MM, DFOV 25, ASIR 60%, thickness 1.25 mm). Finally, the positron emission tomography is acquired: static in 3D mode for 15 minutes, 30 minutes after the injection of 18 FDG, the axial field of view is 25, the matrix in 256 x 256, OSEM reconstruction 6 iterations 24 subsets, attenuation correction, diffused, and PSF. Gaussian filter, cutoff frequency of 4. Obtaining forty-seven contiguous sections of 3.26 mm thick.</description>
    <arm_group_label>Patients with transient global amnesia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with a transient global amnesia according to the criteria of Hodges and&#xD;
        Warlow (1990) in the acute phase (i.e. within 24 hours after the onset of the stroke),&#xD;
        accompanied by a trusted person and admitted to the SAU of the CHU de Nîmes, plus a group&#xD;
        of healthy volunteers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject with no history of transient global amnesia or neurological or psychiatric&#xD;
             pathology.&#xD;
&#xD;
          -  Patients with a transient global amnesia according to the criteria of Hodges and&#xD;
             Warlow (1990) in the acute phase (i.e. within 24 hours after the onset of the stroke),&#xD;
             accompanied by a trusted person&#xD;
&#xD;
          -  The patient must have given their free and informed consent and signed the consent&#xD;
             form&#xD;
&#xD;
          -  The patient must be a member or beneficiary of a health insurance plan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject is participating in another study, or is in a period of exclusion&#xD;
             determined by a previous study&#xD;
&#xD;
          -  The subject refuses to sign the consent&#xD;
&#xD;
          -  It is impossible to give the subject informed information&#xD;
&#xD;
          -  The patient is under safeguard of justice or state guardianship&#xD;
&#xD;
          -  The patient is pregnant or breastfeeding&#xD;
&#xD;
          -  Presence of a focal neurological pathology that may explain the symptoms, history of&#xD;
             epilepsy or psychiatric disorders.&#xD;
&#xD;
          -  Hypersensitivity to iodinated contrast media.&#xD;
&#xD;
          -  Known allergy to 18-FDG.&#xD;
&#xD;
        Non-inclusion criteria concerning control subjects:&#xD;
&#xD;
          -  Presence of disorders on neurological assessment&#xD;
&#xD;
          -  Presence of cognitive disorders on the neuropsychological assessment (z-score &lt;-1.65&#xD;
             on the RBANS or on the Stroop test).&#xD;
&#xD;
        Exclusion criteria for the target population:&#xD;
&#xD;
        • Patients will be excluded after the 1st neuropsychological assessment if episodic memory&#xD;
        tests show complete recovery from anterograde amnesia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Camille Heitz</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nimes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valentina Galetto</last_name>
    <phone>04.66.68.32.61</phone>
    <email>valentina.galetto@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Nimes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>04.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Camille Heitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valentina Galetto</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Thouvenot</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Sébastien Guillamo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent Collombier</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 4, 2020</study_first_submitted>
  <study_first_submitted_qc>September 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amnesia</mesh_term>
    <mesh_term>Amnesia, Transient Global</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

